Glenmark Pharma inks pact with JB Chemicals to divest Razel brand in India, Nepal for Rs 314 crore
The transaction is expected to be closed by the end of this calendar year, Glenmark Pharma said, adding that the divestment is in line with the company's strategy to focus on "other sub‐categories of the cardio‐vascular segment".